Downloads provided by UsageCounts
We studied hepatic steatosis in people with HIV (PWH) who switched to an integrase inhibitor (INSTI)-based regimen. One hundred and fifty-four PWH were included. After 48 weeks, median (Q1–Q3) weight gain was 1.2 (−0.6 to 3.8) kg and median (Q1–Q3) controlled attenuation parameter (CAP) change was −4 (−33 to 27) dB/m. Weight gain was weakly correlated with CAP change [R 2 95% confidence interval (CI) = 0.144 (−0.014 to 0.296); P = 0.074)]. Changes in hepatic steatosis after switching to INSTI-based regimens do not seem to parallel weight gain after 1 year.
Fatty Liver, Humans, Elasticity Imaging Techniques, HIV Infections, HIV Integrase Inhibitors, Weight Gain
Fatty Liver, Humans, Elasticity Imaging Techniques, HIV Infections, HIV Integrase Inhibitors, Weight Gain
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 29 | |
| downloads | 21 |

Views provided by UsageCounts
Downloads provided by UsageCounts